GlassScriptPhysician profile
Steven B Hutto
NPI 1356588529
$13,973.84
in general payments reported to CMS, 2019-2025
47 companies · $2,675 in 2025
The $2,675 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $540 · 2021: $581 · 2022: $2,501 · 2023: $2,706 · 2024: $2,665 · 2025: $2,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,982 · Education: $62.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,982.29 |
| Education | $62.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,695.87 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,832.46 | 2019-2025 | Apretude, Rukobia, Cabenuva |
| Novo Nordisk INC | $1,304.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,175.07 | 2019-2025 | |
| Lilly USA, LLC | $915.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $821.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $790.65 | 2019-2025 | Delstrigo, Pifeltro, Gardasil 9 |
| Glaxosmithkline, LLC. | $689.32 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $612.82 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $412.18 | 2019-2025 | |
| Amgen INC. | $273.07 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $226.34 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Janssen Biotech, INC. | $201.20 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $176.40 | 2022-2023 | Serostim |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hutto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.